Clinical significance of CTHRC1 protein expression in human cancers: a meta-analysis.
The aim of this meta-analysis was to investigate the overall diagnostic and prognostic values of CTHRC1 expression in human cancer development. Based on the inclusion and exclusion criteria, 8 cohort studies were included in the meta-analysis. The data were extracted, and analyses were performed using a random-effects model. Summary odds ratios (ORs) and effect sizes (ESs) with 95% confidence intervals (CIs) were calculated to assess the strength of the associations. A total of 1065 cancer patients from the 8 studies were included in the meta-analysis. The results revealed a positive correlation of CTHRC1 protein expression in tumors with tumor-node-metastasis (TNM) stage and with lymph node (LN) metastasis (TNM: OR = 2.98, 95%CI = 1.48-6.00, P = 0.002; LN: OR = 4.26, 95%CI = 1.88-9.67, P = 0.001). CTHRC1 expression was higher in tumors with sizes ≥5 cm than in tumors with sizes <5 cm (OR = 2.39, 95%CI = 1.12-5.09, P = 0.024). Patients with higher CTHRC1 expression had decreased overall survival (OS) (ES = 1.78, 95%CI = 1.23-2.33, P < 0.001) and poorer disease-free survival (DFS) (ES = 1.71, 95%CI = 1.11-2.31, P < 0.001). Disease-stratified analyses yielded significantly different estimates of CTHRC1 levels in the majority of the subgroups (all P < 0.05). In conclusion, increased CTHRC1 expression is associated with advanced TNM stage, increased LN metastasis and tumor size, and decreased OS and DFS, indicating that CTHRC1 may be a biomarker for prognosis of cancer patients.
Department of Pathology, Linyi People's Hospital of Shandong Province, Linyi, China.
S F
SF
Wang
Department of Ophthalmology, Zoucheng People's Hospital of Shandong Province, Zoucheng, China.
Z
Z
Yin
Health Management Center, Qingdao Haici Medical Treatment Group, Qingdao, China.
J J
JJ
Yin
Department of Emergency, Qingdao Municipal Hospital, Qingdao, China.
W
W
Zhang
Department of Pathology, Yantai Mountain Hospital, Yantai, China.
C G
CG
Dong
D018572:Disease-Free Survival; D016326:Extracellular Matrix Proteins / Q000096:biosynthesis* / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008207:Lymphatic Metastasis; D009367:Neoplasm Staging; D009369:Neoplasms / Q000235:genetics* / Q000473:pathology; D011379:Prognosis; D040901:Proteomics
C502426:CTHRC1 protein, human; D016326:Extracellular Matrix Proteins